SCHEMBL13429129

SCHEMBL13429129

O=c1cc(Oc2ccc(Cl)cc2)c2ccccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 4/20 0.50
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 1/20 0.47
TNKS2 Q9H2K2 1/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.47
KDM4E B2RXH2 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
PDE10A Q9Y233 1/20 0.47
ALDH1A1 P00352 1/20 0.46
IGF1R P08069 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 2/20 0.44
MAPT P10636 1/20 0.44
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A1 P04798 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008835 0.87 HPGD (0.54) RHEBCYP1A2CYP2C19TNKS2KMT2A
SCHEMBL3205961 0.85 CYP1A2 (0.47) CYP1A2CYP2C19TNKS2KMT2AMEN1
SCHEMBL13429212 0.85 CYP1A2 (0.47) CYP1A2CYP2C19TNKS2KMT2AMEN1
SCHEMBL13429113 0.85 HPGD (0.57) CYP1A2CYP2C19TNKS2KMT2AMEN1
SCHEMBL13429075 0.85 CYP1A2 (0.56) CYP1A2CYP2C19TNKS2KMT2AMEN1
SCHEMBL13429066 0.85 KDM4E (0.50) CYP1A2CYP2C19TNKS2KMT2AMEN1
SCHEMBL13429062 0.85 L3MBTL1 (0.60) CYP1A2CYP2C19TNKS2KMT2AMEN1
SCHEMBL13429082 0.85 CYP1A2 (0.47) CYP1A2CYP2C19TNKS2KMT2AMEN1
SCHEMBL13429078 0.84 TP53 (0.54) RHEBCYP1A2CYP2C19KMT2AMEN1
SCHEMBL3217241 0.84 MEN1 (0.60) RHEBCYP1A2CYP2C19KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA RHEB 86/4885CYP1A2 2131/4885CYP2C19 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.